Response to Comments: MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC)

This policy (A56148) is an administrative Response to Comments regarding the MolDX Guardant360® plasma-based comprehensive genomic profiling LCD (DL37366). It records comment and notice period dates and notes the LCD became final on 2018-11-19, but does not itself state coverage, limitation, documentation, or frequency criteria — refer to LCD DL37366 for the actual coverage policy.

"This document is a Response to Comments for MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in NSCLC and references LCD DL37366; it does not contain clinical coverage or billing cr..."

Sign up to see full coverage criteria, indications, and limitations.